Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFZ19J
|
|||
| Drug Name |
BNT141
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Biliary tract cancer [ICD-11: 2C17; ICD-10: C24.9] | Phase 2 | [1] | |
| Gastric cancer [ICD-11: 2B72] | Phase 2 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 2 | [1] | ||
| Company |
BioNTech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.